

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

<b>CLINICAL BENEFIT</b>	<input type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN. <input checked="" type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. <input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE. <input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. <input type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. <input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
<b>Effective Date:</b>	<b>RETIRED 7/1/2026</b>

### POLICY

Use of gene expression analysis, protein biomarkers, and multimodal artificial intelligence (MMAI) to guide management of prostate cancer are considered **investigational** in all situations. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

### Cross-reference:

**MP 2.280 Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer**

### PRODUCT VARIATIONS

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations. Please see additional information below.

**FEP PPO:** Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

### DESCRIPTION/BACKGROUND

#### PROSTATE CANCER

Prostate cancer is the most common cancer diagnosed among men in the U. S, and the second most common cancer overall. Autopsy studies in the era before the availability of prostate-specific antigen (PSA) screening have identified incidental cancerous foci in 30% of men 50 years of age, with incidence reaching 75% at age 80 years.

Localized prostate cancers may appear very similar clinically at diagnosis. However, they often exhibit diverse risk of progression that may not be captured by clinical risk categories (e.g., D'Amico criteria) or prognostic tools based on clinical findings, including PSA titers, Gleason grade, or tumor stage. In studies of conservative management, the risk of localized disease progression based on prostate cancer-specific survival rates at 10 years may range from 15% to 20% to perhaps 27% at 20-year follow-up. Among older men (aged >70 years) with low-risk disease, comorbidities typically supervene as a cause of death; these men will die with prostate

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

cancer present, rather than from cancer itself. Other very similar appearing low-risk tumors may progress unexpectedly rapidly, quickly disseminating and becoming incurable.

### Risk Stratification in Newly Diagnosed Disease

In the U.S., most prostate cancers are clinically localized at diagnosis due in part to the widespread use of PSA testing. Clinicopathologic characteristics are used to stratify patients by risk based on the extent of the primary tumor (T category), nearby lymph node involvement (N category), metastasis (M category), PSA level and Gleason score. The National Comprehensive Cancer Network (NCCN) and American Urological Association risk categories for clinically localized prostate cancer are similar, derived from the D'Amico criteria and broadly include low-, intermediate-, or high-risk as follows as well as subcategories within these groups:

- Low: T1-T2a and Gleason score  $\leq 6$ /Gleason grade group 1 and PSA level  $\leq 10$  ng/mL;
- Intermediate: T2b-T2c or Gleason score 3+4=7/Gleason grade group 2 or Gleason score 4+3=7/Gleason grade group 3 or PSA level 10-20 ng/mL;
- High: T3a or Gleason score 8/Gleason grade group 4 or Gleason score 9-10/Gleason grade group 5 or PSA level  $>20$  ng/mL.

Risk stratification is combined with patient age, life expectancy, and treatment preferences to make initial therapy decisions.

### Principles of Risk Stratification and Biomarkers for Prostate Cancer

Predictive biomarkers and risk stratification methods are the primary tools within clinical practice that may aid in the treatment of individuals with localized and advanced prostate cancer. The NCCN uses multiple categories and subgroupings to capture prognostic risk and provide a method for risk-stratification to allow standardized treatment recommendations for individuals with localized and advanced prostate cancer. These tools are separated by type and category:

Type:

- "Standard Tools: These include clinical and/or pathologic variables routinely collected to assign a patient to an NCCN category and/or subgroup. Examples include TNM stage, Grade Group, PSA, and metastatic volume of disease."
- "Clinical and Pathologic Tools: These include clinical and/or pathologic tools that are generally derived from standard tools. Examples include multivariable models or nomograms, histologic variants, and PSA kinetics."
- "Advanced Tools: These involve an additional test above what is collected to assign an NCCN category or subgroup. These may include, but are not limited to, germline or somatic tests, gene expression tests, digital histopathology-based tests, imaging, and circulating markers."

Category:

- "Prognostic: Discriminates the risk of developing an oncologic endpoint (e.g., distant metastasis). The relative benefit of a treatment (i.e., the treatment effect or hazard ratio)

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

is generally similar across a prognostic spectrum, although the absolute benefit of an intervention may vary by risk (i.e., number needed to treat [NNT])."

- "Prognostic biomarkers independently discriminate and are associated with a clinically meaningful endpoint above and beyond standard tools relevant to that disease setting that ultimately helps guide a therapeutic decision."
- "Predictive: Discriminates a difference in the relative benefit of a specific treatment for an oncologic endpoint."
  - "Predictive biomarkers have been demonstrated to measure a biomarker-treatment interaction that ultimately helps guide a therapeutic decision in the context of a randomized trial, specifically randomizing the treatment of interest."

### Monitoring After Prostatectomy

All normal prostate tissue and tumor tissue are theoretically removed during radical prostatectomy (RP), so the serum level of PSA should be undetectable following RP. Detectable PSA post-RP indicates residual prostate tissue and presumably persistent or recurrent disease. Prostate-specific antigen is serially measured following RP to detect early disease recurrence. The National Comprehensive Cancer Network recommends monitoring serum PSA every 6 to 12 months for the first 5 years and annually thereafter. Many recurrences following RP can be successfully treated. The American Urological Association recommends that biochemical recurrence be defined as a serum PSA of 0.2 ng/mL or higher, which is confirmed by the second determination with a PSA level of 0.2 ng/mL or higher.

### Castration-Resistant Prostate Cancer

Androgen deprivation therapy (ADT) is generally the initial treatment for patients with advanced prostate cancer. Androgen deprivation therapy can produce tumor response and improve quality of life but most patients will eventually progress on ADT. Disease that progresses while the patient is on ADT is referred to as castration-resistant prostate cancer. After progression, continued ADT is generally used in conjunction with other treatments. Androgen pathways are important in the progression of castration-resistant prostate cancer. Several drugs have been developed that either inhibit enzymes involved in androgen production or inhibit the androgen receptor, such as abiraterone and enzalutamide. Taxane chemotherapy with docetaxel or cabazitaxel may also be used after progression. Immunotherapy (sipuleucel-T) or radium 223 are options for select men.

### Decision Framework for Evaluation Prostate Cancer Biomarkers

#### Simon et al Framework

Many studies have investigated individual biomarkers or combinations of biomarkers associated with prostate cancer outcomes. Determining which studies constitute sufficient evidence that the test or biomarker is likely to be clinically useful depends on attributes of the test such as its performance and the quality of the study generating the results. Simon et al (2009) have described a framework to evaluate prognostic biomarker evidence. Study designs, such as prospective clinical trials or previously conducted clinical trials with archived tumor samples,

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

constitute stronger evidence than studies with less planned and systematic patient recruitment and data collection. Randomized trials allow the determination of treatment-biomarker interactions that may be clinically important. In some clinical scenarios, demonstration of a treatment-biomarker interaction is not critical, because the decision to withhold chemotherapy in a low-risk group (to avoid chemotherapy-related morbidity) does not require the presence of a biomarker-treatment interaction. The study must generate an absolute estimate of outcomes in the patient group of interest that would result in a change in management (e.g., withholding of chemotherapy), and the study must have sufficient precision (narrow confidence intervals). Results of the same test across studies should show the consistency of results and more than 1 study demonstrating the desired result should be available. Simon et al (2009) have proposed that at least 2 Simon et al (2009) category B studies showing results consistent with clinical utility are necessary to demonstrate adequate evidence of a biomarker. Simon et al (2009) also proposed that while "further confirmation in a separate trial of the results gained from a category A prospective trial is always welcome, compelling results from such a trial would be considered definitive and no other validating trial would be required."

### REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Prolaris® (Myriad Genetics), Oncotype DX® Prostate and Oncotype DX AR-V7 Nuclear Detect (Genomic Health), Decipher gene expression profiling test (Decipher Corp), the ProMark™ protein biomarker test (Metamark Genetics), and Artera® Prostate Test are available under the auspices of the CLIA. Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of these tests.

In November 2015, the FDA's Office of Public Health Strategy and Analysis published a report suggesting FDA oversight of laboratory-developed tests. The FDA argued that many tests need more FDA oversight than the regulatory requirements of the CLIA. The CLIA standards relate to laboratory operations but do not address inaccuracies or unreliability of specific tests. Prolaris is among the 20 case studies in the document cited as needing FDA oversight. The report asserted that patients are potentially receiving inappropriate prostate cancer care because there is no evidence that results from the test meaningfully improve clinical outcomes.

### RATIONALE

#### SUMMARY OF EVIDENCE

##### Initial Management Decision: Active Surveillance vs Therapeutic Intervention

For individuals who have clinically localized untreated prostate cancer who receive Prolaris, the evidence includes retrospective cohort studies of clinical validity using archived samples in patients of mixed risk categories. Relevant outcomes include overall survival (OS), disease-specific survival, quality of life (QOL), and treatment-related morbidity. For the low-risk group, the Prostate Testing for Cancer and Treatment trial showed 99% 10-year disease-specific

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

survival in mostly low-risk patients receiving active surveillance. The low mortality rate estimated with tight precision makes it unlikely that a test intended to identify a subgroup of low-risk men with a net benefit from immediate treatment instead of active surveillance would find such a group. For the intermediate-risk group, the evidence of improved clinical validity or prognostic accuracy for prostate cancer death using Prolaris Cell Cycle Progression score in patients managed conservatively after a needle biopsy has shown some improvement in areas under the receiver operating characteristic curve over clinicopathologic risk stratification tools. There is limited indirect evidence for potential clinical utility. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have clinically localized untreated prostate cancer who receive Oncotype DX Prostate, the evidence includes case-cohort and retrospective cohort studies of clinical validity using archived samples in patients of mixed risk categories, and a decision-curve analysis examining indirect evidence of clinical utility. Relevant outcomes include OS, disease-specific survival, QOL, and treatment-related morbidity. Evidence for clinical validity and potential clinical utility of Oncotype DX Prostate in patients with clinically localized prostate cancer derives from a study predicting adverse pathology after RP. The validity of using tumor pathology as a surrogate for the risk of progression and cancer-specific death is unclear. It is also unclear whether results from an RP population can be generalized to an active surveillance population. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have clinically localized untreated prostate cancer who receive Decipher Biopsy, the evidence includes retrospective cohort studies of clinical validity using archived samples in intermediate- and high-risk patients and no studies of clinical utility. Relevant outcomes include OS, disease-specific survival, QOL, and treatment-related morbidity. A test designed to identify intermediate-risk men who can receive active surveillance instead of RP or radiotherapy (RT) or high-risk men who can forego androgen deprivation therapy would need to show very high negative predictive value for disease-specific mortality at 10 years and improvement in prediction compared with existing tools used to select such men. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have clinically localized untreated prostate cancer who receive the ProMark protein biomarker test, the evidence includes a retrospective cohort study of clinical validity using archived samples and no studies of clinical utility. Relevant outcomes include OS, disease-specific survival, QOL, and treatment-related morbidity. Current evidence does not support improved outcomes with ProMark given that only a single clinical validity study is available. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have clinically localized untreated prostate cancer who receive ArteraAI Prostate Test, the evidence includes 1 meta-analysis and 5 retrospective analyses on archived samples from randomized clinical trials on prostate cancer patients of mixed risk categories to assess clinical validity and utility. Relevant outcomes include OS, disease-specific survival, QOL, and treatment-related morbidity. Evidence for clinical validity and potential clinical utility of

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

ArteraAI Prostate Test in patients with clinically localized prostate cancer derives from a handful of studies comparing relevant outcomes against comparators like National Comprehensive Cancer Network (NCCN) and standard clinicopathologic risk-stratification tools. Multimodal artificial intelligence (MMAI) algorithms, that form the foundation of ArteraAI, have shown they can outperform comparators at prognosticating 10-year outcomes of interest (OS, distant metastasis [DM], biochemical failure [BF], and prostate cancer-specific survival [PCSS]). Additionally, MMAI was able to demonstrate it is predictive for short-term androgen deprivation therapy (ST-ADT) and can determine if prostate cancer patients would have a better net health outcome on RT alone or RT plus ST-ADT. Limitations of these studies are synonymous with retrospective analysis, including but not limited to, clinical heterogeneity of study populations, variability in data recording, and different conditions under which measurements occurred. No study reported management changes made in response to ArteraAI Prostate Test results, but current NCCN management algorithms recommend MMAI testing with ArteraAI for prostate cancer patients with NCCN intermediate-risk scores to indicate patients that should undergo ST-ADT regardless of RT dose or type. Moreover, NCCN notes that MMAI testing with ArteraAI may provide more accurate risk stratification to enable better management of cancer patients; however, it remains unclear on how this could be used in clinical practice as specific MMAI cutoff values have not been published. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### Management Decision After Radical Prostatectomy

For individuals who have localized prostate cancer treated with RP who receive Prolaris, the evidence includes retrospective cohort studies of clinical validity using archived samples. Relevant outcomes include OS, disease-specific survival, QOL, and treatment-related morbidity. No direct evidence is available to support the clinical utility of Prolaris for improving net outcomes of patients with localized prostate cancer following RP. The chain of evidence is also incomplete. Decision-curve analysis did not provide convincing evidence of meaningful improvement in net benefit by incorporating the cell cycle progression (CCP) score. Evidence of improved clinical validity or prognostic accuracy for prostate cancer death using the Prolaris Cell Cycle Progression score in patients after prostatectomy has shown some improvement in areas under the receiver operating characteristic curve over clinicopathologic risk stratification tools. Although Prolaris CCP score may have an association with biochemical recurrence (BCR), disease-specific survival outcomes were reported in only 1 analysis. A larger number of disease-specific survival events and precision estimates for discrimination measures are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have localized prostate cancer who are treated with RP and who receive the Decipher RP prostate cancer classifier, the evidence includes a study of analytic validity, prospective and retrospective studies of clinical validity using overlapping archived samples, decision-curve analyses examining indirect evidence of clinical utility, and prospective decision-impact studies without pathology or clinical outcomes. Relevant outcomes include OS, disease-specific survival, QOL, and treatment-related morbidity. The clinical validity of the Decipher RP genomic classifier has been evaluated in samples of patients with high-risk prostate cancer undergoing different interventions following RP. Studies reported some incremental

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

improvement in discrimination. However, it is unclear whether there is consistently improved reclassification-particularly to higher risk categories-or whether the test could be used to predict which men will benefit from RT. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have localized prostate cancer treated with RP who receive ArteraAI Prostate Test, the evidence includes 2 retrospective cohort studies of clinical validity using archived samples. Relevant outcomes include OS, disease-specific survival, QOL, and treatment-related morbidity. ArteraAI proved to be prognostic for RP-specific endpoints of BCR and adverse pathology given the statistically significant association. Disease-specific survival outcomes were reported in both studies and the evidence of clinical validity and prognostic accuracy for MMAI scores via ArteraAI testing in patients after RP demonstrated statistically improved PCSM and OS when compared to standard clinicopathologic risk stratification tools. Limitations of these studies are synonymous with retrospective analysis, including but not limited to, clinical heterogeneity of study populations, variability in data recording, and different conditions under which measurements occurred. No study reported management changes made in response to ArteraAI Prostate Test results. Overall, ArteraAI Prostate Test is validated for disease-specific outcomes for prostate cancer patients who underwent RP and can provide additional prognostic information that may guide postoperative management, but further studies are needed to determine if MMAI can be used to decide specific treatment regimens that improve health outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### Management Decision in Castration-Resistant Prostate Cancer

For individuals who have metastatic castration-resistant prostate cancer who receive the Oncotype DX AR-V7 Nuclear Detect, the evidence includes 1 prospective cohort study, 1 retrospective cohort study of clinical validity using archived samples, and no studies of clinical utility. Relevant outcomes include OS, disease-specific survival, QOL, and treatment-related morbidity. Current evidence does not support improved outcomes with Oncotype DX AR-V7 Nuclear Detect, given that only 2 clinical validity studies meeting inclusion criteria were available. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### Management Decision in Castration-Sensitive Prostate Cancer

For individuals who have metastatic castration-sensitive prostate cancer (mCSPC) who receive ArteraAI Prostate Test, the evidence includes 2 retrospective cohort studies of clinical validity using archived samples. Relevant outcomes include OS, disease-specific survival, QOL, and treatment-related morbidity. MMAI was able to estimate treatment effects and determine that MMAI high-risk mCRPC patients would derive benefit from metastasis-directed therapy (MDT) when compared to observation. Limitations of these studies are synonymous with retrospective analysis, including but not limited to, clinical heterogeneity of study populations, variability in data recording, and different conditions under which measurements occurred. No study reported management changes made in response to ArteraAI Prostate Test results. Overall, ArteraAI Prostate Test is prognostic for mCSPC patients and has the potential to guide treatment management, but further studies are needed to determine if MMAI can be used to decide

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

specific treatment regimens that improve net health outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### DEFINITIONS

N/A

### DISCLAIMER

*Capital Blue Cross' medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as permitted by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member's benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the members' benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross' Provider Services or Member Services.*

### CODING INFORMATION

**Note:** This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

#### Investigational; therefore, not covered:

Procedure Codes							
81541	81542	81479	0047U	0376U	0512U	0513U	

### REFERENCES

1. National Cancer Institute. *Cancer Stat Facts: Cancer of Any Site*. <https://seer.cancer.gov/statfacts/html/all.html>. Accessed March 18, 2025.
2. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: review of the current literature. *Cancer*. Apr 15 2008; 112(8): 1650-9. PMID 18306379
3. Bangma CH, Roemeling S, Schröder FH. Overdiagnosis and overtreatment of early detected prostate cancer. *World J Urol*. Mar 2007; 25(1): 3-9. PMID 17364211
4. Johansson JE, Andrén O, Andersson SO, et al. Natural history of early, localized prostate cancer. *JAMA*. Jun 09 2004; 291(22): 2713-9. PMID 15187052

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

5. *Ploussard G, Epstein JI, Montironi R, et al. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol. Aug 2011; 60(2): 291-303. PMID 21601982*
6. *Harnden P, Naylor B, Shelley MD, et al. The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis. Cancer. Mar 01 2008; 112(5): 971-81. PMID 18186496*
7. *Brimo F, Montironi R, Egevad L, et al. Contemporary grading for prostate cancer: implications for patient care. Eur Urol. May 2013; 63(5): 892-901. PMID 23092544*
8. *Eylert MF, Persad R. Management of prostate cancer. Br J Hosp Med (Lond). Feb 2012; 73(2): 95-9. PMID 22504752*
9. *Eastham JA, Kattan MW, Fearn P, et al. Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group. Eur Urol. Feb 2008; 53(2): 347-54. PMID 17544572*
10. *Bill-Axelsson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. May 12 2005; 352(19): 1977-84. PMID 15888698*
11. *Thompson IM, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. Aug 15 2013; 369(7): 603-10. PMID 23944298*
12. *Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. May 04 2005; 293(17): 2095-101. PMID 15870412*
13. *National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf). Accessed March 18, 2025.*
14. *Eastham JA, Aufferberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol. Jul 2022; 208(1): 10-18. PMID 35536144*
15. *Thompson IM, Valicenti RK, Albertsen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. Aug 2013; 190(2): 441-9. PMID 23707439*
16. *Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. Nov 04 2009; 101(21): 1446-52. PMID 19815849*
17. *Food and Drug Administration (FDA). The Public Health Evidence for FDA Oversight of Laboratory Developed Tests: 20 Case Studies. 2015; [http://www.nila-usa.org/images/nila/The%20Public%20Health%20Case%20for%20FDA%20Oversight%20of%20LDTs%20110915\(2\)\\_508ed%20\(1\).pdf](http://www.nila-usa.org/images/nila/The%20Public%20Health%20Case%20for%20FDA%20Oversight%20of%20LDTs%20110915(2)_508ed%20(1).pdf). Accessed March 18, 2025.*
18. *Borley N, Feneley MR. Prostate cancer: diagnosis and staging. Asian J Androl. Jan 2009; 11(1): 74-80. PMID 19050692*
19. *Freedland SJ. Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer. Mar 15 2011; 117(6): 1123-35. PMID 20960523*

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

20. Albertsen PC. Treatment of localized prostate cancer: when is active surveillance appropriate?. *Nat Rev Clin Oncol*. Jul 2010; 7(7): 394-400. PMID 20440282
21. Ip S, Dahabreh IJ, Chung M, et al. An evidence review of active surveillance in men with localized prostate cancer. *Evid Rep Technol Assess (Full Rep)*. Dec 2011; (204): 1-341. PMID 23126653
22. American Urological Association (AUA). Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. 2022; <https://www.auanet.org/guidelines-and-quality/guidelines/clinically-localized-prostate-cancer-uaa/astro-guideline-2022>. Accessed March 18, 2025.
23. Nam RK, Cheung P, Herschorn S, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. *Lancet Oncol*. Feb 2014; 15(2): 223-31. PMID 24440474
24. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. *N Engl J Med*. Oct 13 2016; 375(15): 1415-1424. PMID 27626136
25. Tosoian JJ, Mamawala M, Epstein JI, et al. Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. *J Clin Oncol*. Oct 20 2015; 33(30): 3379-85. PMID 26324359
26. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. *J Clin Oncol*. Jan 20 2015; 33(3): 272-7. PMID 25512465
27. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. *N Engl J Med*. Jul 19 2012; 367(3): 203-13. PMID 22808955
28. Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. *N Engl J Med*. Jul 13 2017; 377(2): 132-142. PMID 28700844
29. van den Bergh RC, Korfage IJ, Roobol MJ, et al. Sexual function with localized prostate cancer: active surveillance vs radical therapy. *BJU Int*. Oct 2012; 110(7): 1032-9. PMID 22260273
30. Johansson E, Steineck G, Holmberg L, et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. *Lancet Oncol*. Sep 2011; 12(9): 891-9. PMID 21821474
31. Wu CL, Schroeder BE, Ma XJ, et al. Development and validation of a 32-gene prognostic index for prostate cancer progression. *Proc Natl Acad Sci U S A*. Apr 09 2013; 110(15): 6121-6. PMID 23533275
32. Spans L, Clinckemalie L, Helsen C, et al. The genomic landscape of prostate cancer. *Int J Mol Sci*. May 24 2013; 14(6): 10822-51. PMID 23708091
33. Schoenborn JR, Nelson P, Fang M. Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. *Clin Cancer Res*. Aug 01 2013; 19(15): 4058-66. PMID 23704282
34. Huang J, Wang JK, Sun Y. Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy. *Curr Opin Urol*. May 2013; 23(3): 189-93. PMID 23385974

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

35. Yu YP, Song C, Tseng G, et al. Genome abnormalities precede prostate cancer and predict clinical relapse. *Am J Pathol.* Jun 2012; 180(6): 2240-8. PMID 22569189
36. Agell L, Hernández S, Nonell L, et al. A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression. *Am J Pathol.* Nov 2012; 181(5): 1585-94. PMID 23083832
37. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. *J Urol.* Jun 2007; 177(6): 2106-31. PMID 17509297
38. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. *J Urol.* Nov 2003; 170(5): 1792-7. PMID 14532778
39. Cooperberg MR, Freedland SJ, Pasta DJ, et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. *Cancer.* Nov 15 2006; 107(10): 2384-91. PMID 17039503
40. Chen RC, Chang P, Vetter RJ, et al. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. *J Natl Cancer Inst.* Jul 2014; 106(7). PMID 25006192
41. Cuzick J, Berney DM, Fisher G, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. *Br J Cancer.* Mar 13 2012; 106(6): 1095-9. PMID 22361632
42. Cuzick J, Stone S, Fisher G, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. *Br J Cancer.* Jul 28 2015; 113(3): 382-9. PMID 26103570
43. Lin DW, Crawford ED, Keane T, et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. *Urol Oncol.* Jun 2018; 36(6): 310.e7-310.e13. PMID 29655620
44. Montironi R, Mazzuccheli R, Scarpelli M, et al. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. *BJU Int.* Jun 2005; 95(8): 1146-52. PMID 15877724
45. Tward JD, Schlomm T, Bardot S, et al. Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy. *Clin Genitourin Cancer.* Aug 2021; 19(4): 296-304.e3. PMID 33608228
46. Crawford ED, Scholz MC, Kar AJ, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. *Curr Med Res Opin.* Jun 2014; 30(6): 1025-31. PMID 24576172
47. Shore N, Concepcion R, Saltzstein D, et al. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. *Curr Med Res Opin.* Apr 2014; 30(4): 547-53. PMID 24320750
48. Shore ND, Kella N, Moran B, et al. Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. *J Urol.* Mar 2016; 195(3): 612-8. PMID 26403586

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

49. Schaink A, Li C, Wells D, et al. Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment. *Ont Health Technol Assess Ser.* 2017; 17(6): 1-75. PMID 28572867
50. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. *Eur Urol.* Sep 2014; 66(3): 550-60. PMID 24836057
51. Cullen J, Rosner IL, Brand TC, et al. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. *Eur Urol.* Jul 2015; 68(1): 123-31. PMID 25465337
52. Whalen MJ, Hackert V, Rothberg MB, et al. Prospective correlation between likelihood of favorable pathology on the 17-Gene Genomic Prostate Score and actual pathological outcomes at radical prostatectomy. *Urol Pract.* Sep 2016;3(5):379-386.
53. Van Den Eeden SK, Lu R, Zhang N, et al. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease. *Eur Urol.* Jan 2018; 73(1): 129-138. PMID 28988753
54. Salmasi A, Said J, Shindel AW, et al. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy. *J Urol.* Sep 2018; 200(3): 564-572. PMID 29524506
55. Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. *J Clin Oncol.* Apr 10 2013; 31(11): 1428-34. PMID 23460710
56. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. *J Clin Oncol.* Dec 20 2005; 23(36): 9067-72. PMID 16172462
57. Epstein JI, Allsbrook WC, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. *Am J Surg Pathol.* Sep 2005; 29(9): 1228-42. PMID 16096414
58. Brand TC, Zhang N, Crager MR, et al. Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score. *Urology.* Mar 2016; 89: 69-75. PMID 26723180
59. Albala D, Kometer MJ, Febbo PG, et al. Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate Score. *Rev Urol.* 2016; 18(3): 123-132. PMID 27833462
60. Eure G, Germany R, Given R, et al. Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort. *Urology.* Sep 2017; 107: 67-75. PMID 28454985
61. Badani KK, Kometer MJ, Febbo PG, et al. The impact of a biopsy based 17-Gene Genomic Prostate Score on treatment recommendations in men with newly diagnosed clinically prostate cancer who are candidates for active surveillance. *Urol Pract.* 2015;2(4):181-189. PMID not Indexed in Pubmed

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

62. Canfield SK, M.J.; Febbo, P.G.; Hornberger, J. Balancing confounding and generalizability using observational, real-world data: 17-gene genomic prostate score assay effect on active surveillance. *Rev Urol.* 2018;20(2):69-76.
63. Canfield S, Kemeter MJ, Hornberger J, et al. Active Surveillance Use Among a Low-risk Prostate Cancer Population in a Large US Payer System: 17-Gene Genomic Prostate Score Versus Other Risk Stratification Methods. *Rev Urol.* 2017; 19(4): 203-212. PMID 29472824
64. Nguyen AM, Carter GC, Wilson LM, et al. Real-world utilization, patient characteristics, and treatment patterns among men with localized prostate cancer tested with the 17-gene genomic prostate score® (GPS TM ) assay. *Prostate.* Jul 2024; 84(10): 922-931. PMID 38666513
65. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Med Decis Making.* 2006; 26(6): 565-74. PMID 17099194
66. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. *J Natl Cancer Inst.* Jun 16 2009; 101(12): 878-87. PMID 19509351
67. Ross AE, Iwata KK, Elsouda D, et al. Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance. *JCO Precis Oncol.* Apr 2024; 8: e2300603. PMID 38635932
68. Berlin A, Murgic J, Hosni A, et al. Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. *Int J Radiat Oncol Biol Phys.* Jan 01 2019; 103(1): 84-91. PMID 30170099
69. Nguyen PL, Shin H, Yousefi K, et al. Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists. *Urology.* Jul 2015; 86(1): 35-40. PMID 26142578
70. Tosoian JJ, Biner SR, Jeffrey Karnes R, et al. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. *Prostate Cancer Prostatic Dis.* Dec 2020; 23(4): 646-653. PMID 32231245
71. Zhu A, Proudfoot JA, Davicioni E, et al. Use of Decipher Prostate Biopsy Test in Patients with Favorable-risk Disease Undergoing Conservative Management or Radical Prostatectomy in the Surveillance, Epidemiology, and End Results Registry. *Eur Urol Oncol.* Jul 06 2024. PMID 38972832
72. Blume-Jensen P, Berman DM, Rimm DL, et al. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. *Clin Cancer Res.* Jun 01 2015; 21(11): 2591-600. PMID 25733599
73. Esteva A, Feng J, van der Wal D, et al. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. *NPJ Digit Med.* Jun 08 2022; 5(1): 71. PMID 35676445
74. Spratt DE, Tang S, Sun Y, et al. Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. *NEJM Evid.* Aug 2023; 2(8): EVIDoA2300023. PMID 38320143

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

75. Gerrard P, Zhang J, Yamashita R, et al. Analytical Validation of a Clinical Grade Prognostic and Classification Artificial Intelligence Laboratory Test for Men with Prostate Cancer. *AI in Precision Oncology* 2024 1:2, 119-126.
76. Spratt DE, Liu VYT, Jia AY, et al. Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials. *Eur Urol.* Oct 2024; 86(4): 369-371. PMID 39025748
77. Ross AE, Zhang J, Huang HC, et al. External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial. *Eur Urol Oncol.* Oct 2024; 7(5): 1024-1033. PMID 38302323
78. Tward JD, Huang HC, Esteva A, et al. Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology. *JCO Precis Oncol.* Oct 2024; 8: e2400145. PMID 39447096
79. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA.* Sep 16 1998; 280(11): 969-74. PMID 9749478
80. Fossati N, Karnes RJ, Boorjian SA, et al. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. *Eur Urol.* Jun 2017; 71(6): 886-893. PMID 27484843
81. Hwang WL, Tendulkar RD, Niemierko A, et al. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. *JAMA Oncol.* May 10 2018; 4(5): e175230. PMID 29372236
82. Buscariollo DL, Drumm M, Niemierko A, et al. Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. *Pract Radiat Oncol.* 2017; 7(2): e125-e133. PMID 28274403
83. Freedland SJ, Rumble RB, Finelli A, et al. Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement. *J Clin Oncol.* Dec 01 2014; 32(34): 3892-8. PMID 25366677
84. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. *J Clin Oncol.* May 20 2007; 25(15): 2035-41. PMID 17513807
85. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. *J Clin Oncol.* Oct 01 2005; 23(28): 7005-12. PMID 16192588
86. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. *Cancer.* Nov 15 2011; 117(22): 5039-46. PMID 21647869
87. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. *Lancet Oncol.* Mar 2011; 12(3): 245-55. PMID 21310658

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

88. Bishoff JT, Freedland SJ, Gerber L, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. *J Urol.* Aug 2014; 192(2): 409-14. PMID 24508632
89. Swanson GP, Lenz L, Stone S, et al. Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone. *Prostate.* Mar 2021; 81(4): 261-267. PMID 33475174
90. Koch MO, Cho JS, Kaimakliotis HZ, et al. Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. *Cancer Biomark.* Jun 07 2016; 17(1): 83-8. PMID 27314296
91. Freedland SJ, Gerber L, Reid J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. *Int J Radiat Oncol Biol Phys.* Aug 01 2013; 86(5): 848-53. PMID 23755923
92. Klein EA, Yousefi K, Haddad Z, et al. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. *Eur Urol.* Apr 2015; 67(4): 778-86. PMID 25466945
93. Sommariva S, Tarricone R, Lazzeri M, et al. Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol.* Jan 2016; 69(1): 107-15. PMID 25481455
94. Morgan TM, Daignault-Newton S, Spratt DE, et al. Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial. *Eur Urol.* Feb 2025; 87(2): 228-237. PMID 39379238
95. Feng FY, Huang HC, Spratt DE, et al. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. *JAMA Oncol.* Apr 01 2021; 7(4): 544-552. PMID 33570548
96. Den RB, Yousefi K, Trabulsi EJ, et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. *J Clin Oncol.* Mar 10 2015; 33(8): 944-51. PMID 25667284
97. Den RB, Feng FY, Showalter TN, et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. *Int J Radiat Oncol Biol Phys.* Aug 01 2014; 89(5): 1038-1046. PMID 25035207
98. Cooperberg MR, Davicioni E, Crisan A, et al. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. *Eur Urol.* Feb 2015; 67(2): 326-33. PMID 24998118
99. Ross AE, Feng FY, Ghadessi M, et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. *Prostate Cancer Prostatic Dis.* Mar 2014; 17(1): 64-9. PMID 24145624
100. Karnes RJ, Bergstralh EJ, Davicioni E, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. *J Urol.* Dec 2013; 190(6): 2047-53. PMID 23770138
101. Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. *PLoS One.* 2013; 8(6): e66855. PMID 23826159

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

102. Ross AE, Johnson MH, Yousefi K, et al. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. *Eur Urol.* Jan 2016; 69(1): 157-65. PMID 26058959
103. Freedland SJ, Choeurng V, Howard L, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. *Eur Urol.* Oct 2016; 70(4): 588-596. PMID 26806658
104. Glass AG, Leo MC, Haddad Z, et al. Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting. *J Urol.* Jun 2016; 195(6): 1748-53. PMID 26626216
105. Klein EA, Haddad Z, Yousefi K, et al. Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. *Urology.* Apr 2016; 90: 148-52. PMID 26809071
106. Spratt DE, Dai DLY, Den RB, et al. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. *Eur Urol.* Jul 2018; 74(1): 107-114. PMID 29233664
107. Karnes RJ, Choeurng V, Ross AE, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. *Eur Urol.* Feb 2018; 73(2): 168-175. PMID 28400167
108. Ross AE, Den RB, Yousefi K, et al. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. *Prostate Cancer Prostatic Dis.* Sep 2016; 19(3): 277-82. PMID 27136742
109. Lobo JM, Dicker AP, Buerki C, et al. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis. *PLoS One.* 2015; 10(3): e0116866. PMID 25837660
110. West TA, Kiely BE, Stockler MR. Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: a systematic review of randomised trials. *Eur J Cancer.* Jul 2014; 50(11): 1916-24. PMID 24825113
111. Scher HI, Graf RP, Schreiber NA, et al. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. *Eur Urol.* Jun 2017; 71(6): 874-882. PMID 27979426
112. Armstrong AJ, Halabi S, Luo J, et al. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. *J Clin Oncol.* May 01 2019; 37(13): 1120-1129. PMID 30865549
113. Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. *J Urol.* Mar 2018; 199(3): 683-690. PMID 29203269
114. Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. *J Urol.* Apr 2018; 199(4): 990-997. PMID 29331546
115. Li EV, Ren Y, Griffin J, et al. An Artificial Intelligence-Digital Pathology Algorithm Predicts Survival After Radical Prostatectomy From the Prostate, Lung, Colorectal, and Ovarian Cancer Trial. *J Urol.* Jan 22 2025: 101097JU0000000000004435. PMID 39841869

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

116. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. *N Engl J Med*. Sep 11 2014; 371(11): 1028-38. PMID 25184630
117. Scher HI, Lu D, Schreiber NA, et al. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. *JAMA Oncol*. Nov 01 2016; 2(11): 1441-1449. PMID 27262168
118. Scher HI, Graf RP, Schreiber NA, et al. Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. *JAMA Oncol*. Sep 01 2018; 4(9): 1179-1186. PMID 29955787
119. Feng FY, Smith MR, Saad F, et al. Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer. *JCO Precis Oncol*. Jan 2025; 9: e2400653. PMID 39889245
120. Markowski MC, Ren Y, Tierney M, et al. Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer. *Eur Urol Oncol*. Dec 10 2024. PMID 39665917
121. Wang JH, Deek MP, Mendes AA, et al. Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer. *Radiother Oncol*. Jan 2025; 202: 110618. PMID 39510141
122. Eggener SE, Rumble RB, Armstrong AJ, et al. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. *J Clin Oncol*. May 01 2020; 38(13): 1474-1494. PMID 31829902
123. Lowrance WT, Murad MH, Oh WK, et al. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. *J Urol*. Dec 2018; 200(6): 1264-1272. PMID 30086276
124. National Institute for Health and Care Excellence (NICE). Prostate cancer: diagnosis and management [NG131]. 2019 (Updated 2021); <https://www.nice.org.uk/guidance/ng131>. Accessed March 18, 2025.

### POLICY HISTORY

<b>MP 2.263</b>	<b>01/01/2020 Administrative Update.</b> Added new code 81542.
	<b>08/19/2020 Consensus Review.</b> Policy statement unchanged. References and Rationale updated.
	<b>12/30/2020 Retirement Review.</b> Policy will now be managed on 2.280
	<b>10/09/2025 Major Review.</b> Policy to be reinstated as INV only policy.
	<b>03/03/2026 Retirement Review.</b> Services to be managed by Evicore.

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company®

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>GENE EXPRESSION PROFILING, PROTEIN BIOMARKERS, AND MULTIMODAL ARTIFICIAL INTELLIGENCE FOR PROSTATE CANCER MANAGEMENT</b>
<b>POLICY NUMBER</b>	<b>MP 2.263</b>

*and Keystone Health Plan® Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.*

RETIRED